HOME ·

R&D Progress

INSILICO (03696.HK): AI-Driven Candidate Rentosertib Completes First Patient Dosing in Phase III IPF Trial
Tags：
Insilico03696.HKR&D Progress
2026-09-10
LIFETECH SCI (01302.HK): Aortic Valve Replacement System Enters NMPA Innovative Medical Device Special Review Procedure
Tags：
LIFETECH SCI01302.HKR&D Progress
2026-09-10
STAR SPORTS MED (01609.HK): First Chinese Sports Medicine Manufacturer with Full Product Line EU CE MDR Certified
Tags：
STAR SPORTS MED01609.HKR&D Progress
2026-09-10
HBM HOLDINGS-B (02142.HK): Partner Solstice Oncology Closes USD 225 Million Series A Financing
Tags：
HBM HOLDINGS-B02142.HKR&D Progressfinancing
2026-09-09
HENGRUI PHARMA (01276.HK): NMPA Accepts Marketing Application for Ruippotipeptide Injection for Adults with Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-09
CSPC PHARMA (01093.HK): SYH9087, China's First Subcutaneous Rotigotine Long-acting Product, Cleared for Clinical Trials
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-09
HBM HOLDINGS-B (02142.HK): Positive Phase II Interim Results for HBM9378/WIN378 in Asthma; Phase III Initiated
Tags：
HBM HOLDINGS-B02142.HKR&D Progress
2026-09-08
SKB BIO (06990.HK): Positive Phase II Interim Results for SKB378/WIN378 in Asthma; Phase III Initiated
Tags：
SKB BIO06990.HKR&D Progress
2026-09-08
ASCLETIS-B (01672.HK): Initiates US Phase I Study of Oral Amylin Receptor Agonist Peptide ASC36 for Obesity; Up to 13.2% Weight Loss in Non-human Primates
Tags：
ASCLETIS-B01672.HKR&D Progress
2026-09-08
SBP GROUP (01177.HK): Preclinical Data of Oral STAT6 Degrader TQH5528 Presented at ERS 2026
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-08
FOSUN PHARMA (02196.HK): FXS5626 Approved for Phase II/III Trial in Non-Segmental Vitiligo
Tags：
FOSUN PHARMA02196.HKR&D Progress
2026-09-08
UNITED LAB (03933.HK): UBT251 injection completes first participant dosing in Phase III clinical study for type 2 diabetes in China
Tags：
UNITED LAB03933.HKR&D Progress
2026-09-07
MICROTECH MED-B (02235.HK): Next-generation CGM AiDEX G9 obtains NMPA registration approval for marketing
Tags：
MICROTECH MED-B02235.HKR&D Progress
2026-09-07
SBP GROUP (01177.HK): Phase I data of TQC3721 dry powder inhaler (PDE3/4 inhibitor) presented at ERS 2026, showing dose-dependent lung function improvement in COPD
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-07
TENNOR THERAP-B (06872.HK): Positive Phase IIa Proof-of-Concept Data for Rifaquizalone (TNP-2092) in Prosthetic Joint Infection; Multicenter Phase IIb Initiated
Tags：
TENNOR THERAP-B06872.HKR&D Progress
2026-09-07
KINTOR PHARMA-B (09939.HK): Long-Term Safety Trial of KT-939 Completed; No Skin Adverse Reactions in 114 Subjects Over 52 Weeks
Tags：
KINTOR PHARMA-B09939.HKR&D Progress
2026-09-07
CLOVER BIO-B (02197.HK): Positive Phase II Data for Respiratory Combo Vaccine Candidates in Australian Elderly
Tags：
CLOVER BIO-B02197.HKR&D Progress
2026-09-07
HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for oral GLP-1 weight-loss drug HRS-7535 tablets
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-09-04
SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China
Tags：
SIMCERE PHARMA02096.HKR&D Progress
2026-09-04
SBP GROUP (01177.HK): FDA Approves IND Application for Self-Developed Class 1 Drug TQB6426 "GPC3 ADC" for Advanced Malignant Tumors
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-03
Previous1 234